Advertisement

Complement Receptor Type 1

  • G. D. Ross
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 178)

Overview

This review will focus on the complement receptor type 1 (CR1, CD35) expressed by erythrocytes and will cover its structure, molecular biology, and function as a membrane inhibitor of complement activation. The CR1 present on phagocytic cells and lymphocytes has similar functions in regulation of complement activation and serves as a receptor responsible for triggering cellular activation events such as phagocytosis or Ig synthesis. These latter receptor functions of CR1 are not covered in this review, and the reader is referred to several past reviews about leukocyte CR1 for this information (Ross and Medof 1985; Wright and Griffin 1985; Fearon and Ahearn 1989; Ross et al. 1989). Erythrocyte CR1 has three functions in regulation of complement activation that are covered in this review: (a) inhibition of the C3 and C5 convertases of the classical and alternative pathways of complement activation; (b) factor I cofactor activity for cleavage of C3b and iC3b; (c) adsorption of soluble immune complexes, thereby inhibiting complement-mediated inflammation. Table 1 summarizes the attributes of CR1 on all cell types.

Keywords

Systemic Lupus Erythematosus Complement Receptor Cofactor Activity Short Consensus Repeat Soluble Immune Complex 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bartow TJ, Klickstein LB, Fearon DT (1989) Localization of monoclonal antibody epitopes on CR1 by deletion mutagenesis. Compl Inflamm 6: 312 (abstract)Google Scholar
  2. Becherer JD, Lambris JD (1988) Identification of the C3b receptor-binding domain in third component of complement. J Biol Chem 263: 14586–14591PubMedGoogle Scholar
  3. Brown HC, Broom JC (1938) Studies in trypanosomiasis. II. Observations on the red cell adhesion test. Trans R Soc Trop Med Hyg 32: 209–222CrossRefGoogle Scholar
  4. Carroll MC, Alicot EM, Katzman PJ, Klickstein LB, Smith JA, Fearon DT (1988) Organization of the genes encoding complement receptors type 1 and 2, decay-accelerating factor, and C4-binding protein in the RCA locus on human chromosome 1. J Exp Med 167: 1271–1280PubMedCrossRefGoogle Scholar
  5. Chevalier J, Kazatchkine MD (1989) Distribution in clusters of complement receptor type one (CR1) on human erythrocytes. J Immunol 142: 2031–2036PubMedGoogle Scholar
  6. Cohen JHM, Autran B, Jouvin MH, Aubry JP, Rozenbaum W, Banchereau J, Debre P, Revillard JP, Kazatchkine M (1988) Decreased expression of the receptor for the C3b fragment of complement on erythrocytes of patients with acquired immunodeficiency syndrome. Presse Med 17: 727–730PubMedGoogle Scholar
  7. Cooper NR (1969) Immune adherence by the fourth component of complement. Science 165: 396–398PubMedCrossRefGoogle Scholar
  8. Cornacoff JB, Hebert LA, Smead WL, VanAman ME, Birmingham DJ, Waxman FJ (1983) Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest 71: 236–247PubMedCrossRefGoogle Scholar
  9. Cosio FG, Xiao-Ping S, Birmingham DJ, Aman MV, Hebert LA (1990) Evaluation of the mechanisms responsible for the reduction in erythrocyte complement receptors when immune complexes form in vivo in primates. J Immunol 145: 4198–4206PubMedGoogle Scholar
  10. Crawford MH, Grover FL, Kolb WP, McMahan CA, O’Rourke RA, McManus LM, Pinckard RN (1988) Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation 78: 1449–1458PubMedCrossRefGoogle Scholar
  11. Davies KA, Hird V, Stewart S, Sivolapenko GB, Jose P, Epenetos AA, Walport MJ (1990) A study of in vivo immune complex formation and clearance in man. J Immunol 144: 4613–4620PubMedGoogle Scholar
  12. Dobson NJ, Lambris JD, Ross GD (1981) Characteristics of isolated erythrocyte complement receptor type one (CR1, C4b-C3b receptor) and CR1-specific antibodies. J Immunol 126: 693–698PubMedGoogle Scholar
  13. Duke HL, Wallace JM (1930) “Red-cell adhesion” in trypanosomiasis of man and animals. Parasitology 22: 414–456CrossRefGoogle Scholar
  14. Dunckley H, Gatenby PA, Hawkins B, Naito S, Serjeantson SW (1987) Deficiency of C4A is a genetic determinant of systemic lupus erythematosus in three ethnic groups. J Immunogenet 14: 209–218PubMedCrossRefGoogle Scholar
  15. Dykman TR, Cole JL, Iida K, Atkinson JP (1983) Polymorphism of human erythrocyte C3b/C4b receptor. Proc Natl Acad Sci USA 80: 1698–1702PubMedCrossRefGoogle Scholar
  16. Dykman TR, Hatch JA, Atkinson JP (1984) Polymorphism of the human C3b/C4b receptor. Identification of a third allele and analysis of receptor phenotypes in families and patients with systemic lupus erythematosus. J Exp Med 159: 691–703PubMedCrossRefGoogle Scholar
  17. Dykman TR, Hatch JA, Aqua MS, Atkinson JP (1985) Polymorphism of the C3b/C4b receptor (CR1): characterization of a fourth allele. J Immunol 134: 1787–1789PubMedGoogle Scholar
  18. Fearon DT (1979) Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA 76: 5867–5871PubMedCrossRefGoogle Scholar
  19. Fearon DT (1980) Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med 152: 20–30PubMedCrossRefGoogle Scholar
  20. Fearon DT, Ahearn JM (1989) Complement receptor type 1 (C3b/C4b receptor, CD35) and complement receptor type 2 (C3d/Epstein-Barr virus receptor; CD21). In: Lambris JD (ed) The third component of complement. Chemistry and biology. Springer, Berlin Heidelberg New York, pp 83–98 (Current topics in microbiology and immunology, vol 153)Google Scholar
  21. Fielder AHL, Walport MJ, Batchelor JR, Rynes Rl, Black CM, Dodi IA, Hughes GRV (1983) Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J 286: 425–428CrossRefGoogle Scholar
  22. Fischer E, Appay MD, Cook J, Kazatchkine MD (1986) Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor. J Immunol 136: 1373–1377PubMedGoogle Scholar
  23. Gatenby PA, Barbosa JE, Lachmann PJ (1990) Differences between C4A and C4B in the handling of immune complexes: the enhancement of CR1 binding is more important than the inhibition of immunoprecipitation. Clin Exp Immunol 79: 158–163PubMedCrossRefGoogle Scholar
  24. Gigli I, Nelson RA Jr (1968) Complement dependent immune phagocytosis. I. Requirements for C’1, C’2, C’3, C’4. Exp Cell Res 51: 45–67PubMedCrossRefGoogle Scholar
  25. Henson PM (1969) The adherence of leucocytes and platelets induced by fixed IgG antibody or complement. Immunology 16: 107–121PubMedGoogle Scholar
  26. lida K, Nussenzweig V (1981) Complement receptor is an inhibitor of the complement cascade. J Exp Med 153: 1138–1150PubMedCrossRefGoogle Scholar
  27. lida K, Nussenzweig V (1983) Functional properties of membrane-associated complement receptor CR1. J Immunol 130: 1876–1880PubMedGoogle Scholar
  28. lida K, Mornaghi R, Nussenzweig V (1982) Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med 155: 1427–1438PubMedCrossRefGoogle Scholar
  29. Janatova J, Gobel RJ (1985) Activation and fragmentation of the third (C3) and the fourth (C4) components of complement: generation and isolation of physiologically relevant fragments C3c and C4c. J Immunol Methods 85: 17–26PubMedCrossRefGoogle Scholar
  30. Janatova J, Reid KBM, Willis AC (1989) Disulfide bonds are localized within the short consensus repeat units of complement regulatory proteins: C4b-binding protein. Biochemistry 28: 4754–4761PubMedCrossRefGoogle Scholar
  31. Kazatchkine MD, Fearon DT, Austen KF (1979) Human alternative complement pathway: membrane- associated sialic acid regulates the competition between B and β1H for cell-bound C3b. J Immunol 122: 75–80PubMedGoogle Scholar
  32. Klickstein LB, Wong WW, Smith JA, Weis JH, Wilson JG, Fearon DT (1987) Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristic of C3/C4 binding proteins. J Exp Med 165: 1095–1112PubMedCrossRefGoogle Scholar
  33. Klickstein LB, Bartow TJ, Miletic V, Rabson LD, Smith JA, Fearon DT (1988) Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med 168: 1699–1717PubMedCrossRefGoogle Scholar
  34. Lublin DM, Liszewski MK, Post TW, Arce MA, Le Beau MM, Rebentisch MB, Lemons RS, Seya T, Atkinson JP (1988) Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP). J Exp Med 168: 181–194PubMedCrossRefGoogle Scholar
  35. Marks RM, Todd RF III, Ward PA (1989) Rapid induction of neutrophil-endothelial adhesion by endothelial complement fixation. Nature 339: 314–317PubMedCrossRefGoogle Scholar
  36. Medicus RG, Melamed J, Arnaout MA (1983) Role of human factor I and C3b receptor in the cleavage of surface-bound C3b. Eur J Immunol 13: 465–470PubMedCrossRefGoogle Scholar
  37. Medof ME, Nussenzweig V (1984) Control of the function of substrate-bound C4b-C3b by the complement receptor CR1. J Exp Med 159: 1669–1685PubMedCrossRefGoogle Scholar
  38. Medof ME, Oger JJ-F (1982) Competition for immune complexes by red cells in human blood. J Clin Lab Immunol 7: 7–13PubMedGoogle Scholar
  39. Medof ME, Iida K, Mold C, Nussenzweig V (1982) Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med 156: 1739–1754PubMedCrossRefGoogle Scholar
  40. Medof ME, Kinoshita T, Nussenzweig V (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 160: 1558–1578PubMedCrossRefGoogle Scholar
  41. Medof ME, Gottlieb A, Kinoshita T, Hall S, Silber R, Nussenzweig V, Rosse WF (1987) Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest 80: 165–174PubMedCrossRefGoogle Scholar
  42. Moldenhauer F, David J, Fielder AHL, Lachmann PJ, Walport MJ (1987) Inherited deficiency of erythrocyte complement receptor type 1 does not cause susceptibility to systemic lupus erythematosus. Arthritis Rheum 30: 961–966PubMedCrossRefGoogle Scholar
  43. Nelson RA Jr (1953) The immune adherence phenomenon: an immunologically specific reaction between micro-organisms and erythrocytes leading to enhanced phagocytosis. Science 118: 733–737PubMedCrossRefGoogle Scholar
  44. Nishioka K, Linscott WD (1963) Components of guinia pig complement. I. Separation of a serum fraction essential for immune hemolysis and immune adherence. J Exp Med 118: 767–793PubMedCrossRefGoogle Scholar
  45. Nourshargh S, Rampart M, Hellewell PG, Jose PJ, Harlan JM, Edwards AJ, Williams TJ (1989) Accumulation of 111ln-neutrophils in rabbit skin in allergic and non-allergic inflammatory reactions in vivo. Inhibition by neutrophil pretreatment in vitro with a monoclonal antibody recognizing the CD18 antigen. J Immunol 142: 3193–3198PubMedGoogle Scholar
  46. Paccaud J-P, Carpentier J-L, Schifferli JA (1990) Difference in the clustering of complement receptor type 1 (CR1) on polymorphonuclear leukocytes and erythrocytes: effect on immune adherence. Eur J Immunol 20: 283–289PubMedCrossRefGoogle Scholar
  47. Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1977) Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein β1H for cleavage of C3b and C4b in solution. J Exp Med 146: 257–270PubMedCrossRefGoogle Scholar
  48. Rey-Campos J, Rubinstein P, Rodriguez de Cordoba S (1988) A physical map of the human regulator of complement activation gene cluster linking the complement genes CR1, CR2, DAF, and C4BP J Exp Med 167: 664–669PubMedCrossRefGoogle Scholar
  49. Ross GD, Lambris JD (1982) Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes. J Exp Med 155: 96–110PubMedCrossRefGoogle Scholar
  50. Ross GD, Medof ME (1985) Membrane complement receptors specific for bound fragments of C3. Adv Immunol 37: 217–267PubMedCrossRefGoogle Scholar
  51. Ross GD, Polley MJ (1975) Specificity of human lymphocyte complement receptors. J Exp Med 141: 1163–1180PubMedCrossRefGoogle Scholar
  52. Ross GD, Lambris JD, Cain JA, Newman SL (1982) Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immunol 129: 2051–2060PubMedGoogle Scholar
  53. Ross GD, Newman SL, Lambris JD, Devery-Pocius JE, Cain JA, Lachmann PJ (1983) Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin. J Exp Med 158: 334–352PubMedCrossRefGoogle Scholar
  54. Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller CR, Taylor RP, Myones BL, Lachmann PJ (1985) Disease-associated loss of erythrocyte complement receptors (CR1, C3b-receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J Immunol 135: 2005–2014PubMedGoogle Scholar
  55. Ross GD, Walport MJ, Hogg N (1989) Receptors for IgG Fc and fixed C3. In: Asherson GL, Zembala M (eds) Human monocytes. Academic, London, pp 123–139Google Scholar
  56. Schifferli JA, Ng YC, Peters DK (1986) The role of complement and its receptor in the elimination of immune complexes. N Engl J Med 315: 488–495PubMedCrossRefGoogle Scholar
  57. Schifferli JA, Ng YC, Estreicher J, Walport MJ (1988) The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans. Complement- and erythrocyte complement receptor 1-dependent mechanisms. J immunol 140: 899–904PubMedGoogle Scholar
  58. Schifferli JA, Ng YC, Paccaud J-P, Walport MJ (1989) The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans. Clin Exp Immunol 75: 329–335PubMedGoogle Scholar
  59. Seya T, Hara T, Matsumoto M, Sugita Y, Akedo H (1990) Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46). J Exp Med 172: 1673–1680PubMedCrossRefGoogle Scholar
  60. Simpson PJ, Todd RF III, Mickelson JK, Fantone JC, Gallagher KP, Lee KA, Tamura Y, Cronin M, Lucchesi BR (1990) Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function. Circulation 81: 226–237PubMedCrossRefGoogle Scholar
  61. Tamura N, Nelson RA Jr (1967) Three naturally occurring inhibitors of components of complement in guinea pig and rabbit serum. J Immunol 99: 582–589PubMedGoogle Scholar
  62. Tausk F, Harpster E, Gigli I (1990) The expression of C3b receptors in the differentiation of discoid lupus erythematosus and systemic lupus erythematosus. Arthiritis Rheum 33: 888–892CrossRefGoogle Scholar
  63. Tausk FA, McCutchan JA, Spechko P. Schreiber RD, Gigli I (1986) Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J Clin Invest 78: 977–982PubMedCrossRefGoogle Scholar
  64. Tebib JG, Martinez C, Granados J, Alarcon-Segovia D, Schur PH (1989) The frequency of complement receptor type 1 (CR1) gene polymorphisms in nine families with multiple cases of systemic lupus erythematosus. Arthritis Rheum 32: 1465–1469PubMedCrossRefGoogle Scholar
  65. Thomsen BS, Nielsen H, Andersen V (1987) Erythrocyte CR1 (C3b/C4b receptor) levels and disease activity in patients with SLE. Scand J Rheumatol 16: 339–346PubMedCrossRefGoogle Scholar
  66. Vedeler CA, Matre R (1988) Complement receptor CR1 on human peripheral nerve fibres. J Neuroimmunol 17: 315–322PubMedCrossRefGoogle Scholar
  67. Vedeler CA, Matre R (1990) Peripheral nerve CR1 express in situ cofactor activity for degradation of C3b. J Neuroimmunol 26: 51–56PubMedCrossRefGoogle Scholar
  68. Vedeler CA, Matre R, Fischer E (1989) Isolation and characterization of complement receptors CR1 from human peripheral nerves. J Neuroimmunol 23: 215–221PubMedCrossRefGoogle Scholar
  69. Vedeler CA, Scarpini E, Beretta S, Doronzo R, Matre R (1990) The ontogenesis of Fcγ receptors and complement receptors CR1 in human peripheral nerve. Acta Neuropathol (Berl) 80: 35–40CrossRefGoogle Scholar
  70. Wallace JM, Wormall A (1931) Red-cell adhesion in trypanosomiasis of man and other animals; some experiments on mechanism of reaction. Parasitology 23: 346–359Google Scholar
  71. Walport MJ, Ross GD, Mackworth-Young C, Watson JV, Hogg N, Lachmann PJ (1985) Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol 59: 547–554PubMedGoogle Scholar
  72. Walport MJ, Ng YC, Lachmann PJ (1987) Erythrocytes transfused into patients with SLE and haemolytic anaemia lose complement receptor type 1 from their cell surface. Clin Exp Immunol 69: 501–507PubMedGoogle Scholar
  73. Weis JH, Morton CC, Bruns GAP, Weis JJ, Klickstein LB, Wong WW, Fearon DT (1987) A complement receptor locus: genes encoding C3b/C4 receptor and C3d/Epstein-Barr virus receptor map to 1q32. J Immunol 138: 312–315PubMedGoogle Scholar
  74. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT (1990) Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249: 146–151PubMedCrossRefGoogle Scholar
  75. Wilson JG, Wong WW, Schur PH, Fearon DT (1982) Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med 307: 981–986PubMedCrossRefGoogle Scholar
  76. Wilson JG, Murphy EE, Wong WW, Klickstein LB, Weis JH, Fearon DT (1986) Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. J Exp Med 164: 50–59PubMedCrossRefGoogle Scholar
  77. Wong WW, Wilson JG, Fearon DT (1983) Genetic regulation of a structural polymorphism of human C3b receptor. J Clin Invest 72: 685–693PubMedCrossRefGoogle Scholar
  78. Wong WW, Klickstein LB, Smith JA, Weis JH, Fearon DT (1985) Identification of a partial cDNA clone for the human receptor for complement fragments C3b/C4b. Proc Natl Acad Sci USA 82: 7711–7715PubMedCrossRefGoogle Scholar
  79. Wong WW, Cahill JM, Rosen MD, Kennedy CA, Bonaccio ET, Morris MJ, Wilson JG, Klickstein LB, Fearon DT (1989) Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1 -like allele. J Exp Med 169: 847–863PubMedCrossRefGoogle Scholar
  80. Wright SD, Griffin FM Jr (1985) Activation of phagocytic cells’ C3 receptors for phagocytosis. J Leukocyte Biol 38: 327–339PubMedGoogle Scholar
  81. Yeh CG, Marsh HC Jr, Carson GR, Berman L, Concino MF, Scesney SM, Kuestner RE, Skibbens R, Donahue KA, Ip SH (1991) Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats. J Immunol 146: 250–256PubMedGoogle Scholar
  82. Yen J-H, Liu H-W, Lin S-F, Chen J-R, Chen T-P (1989) Erythrocyte complement receptor type 1 in patients with systemic lupus erythematosus. J Rheumatol 16: 1320–1325PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • G. D. Ross
    • 1
  1. 1.Department of Microbiology and ImmunologyUniversity of LouisvilleLouisvilleUSA

Personalised recommendations